$-0.05 EPS Expected for IntelliPharmaCeutics International Inc. (IPCI); Atossa Genetics (ATOS) Shorts Raised By 34.67%

March 15, 2018 - By Adrian Mccoy

Analysts expect IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) to report $-0.05 EPS on April, 10.They anticipate $0.02 EPS change or 28.57% from last quarter’s $-0.07 EPS. After having $-0.08 EPS previously, IntelliPharmaCeutics International Inc.’s analysts see -37.50% EPS growth. The stock increased 15.77% or $0.088 during the last trading session, reaching $0.649. About 897,327 shares traded or 138.53% up from the average. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has risen 16.57% since March 15, 2017 and is uptrending. It has underperformed by 0.13% the S&P500.

Atossa Genetics Inc (NASDAQ:ATOS) had an increase of 34.67% in short interest. ATOS’s SI was 2.05M shares in March as released by FINRA. Its up 34.67% from 1.52 million shares previously. With 11.90 million avg volume, 0 days are for Atossa Genetics Inc (NASDAQ:ATOS)’s short sellers to cover ATOS’s short positions. The stock increased 1.12% or $0.007 during the last trading session, reaching $0.586. About 2.34 million shares traded. Atossa Genetics Inc. (NASDAQ:ATOS) has declined 86.91% since March 15, 2017 and is downtrending. It has underperformed by 103.61% the S&P500.

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, March 5 by H.C. Wainwright. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has “Buy” rating given on Thursday, December 31 by Maxim Group. H.C. Wainwright maintained the shares of IPCI in report on Monday, February 12 with “Buy” rating. The company was maintained on Friday, July 21 by Maxim Group. The stock of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) earned “Buy” rating by Maxim Group on Tuesday, June 6. The rating was downgraded by Maxim Group on Friday, February 16 to “Hold”. The stock has “Buy” rating by Maxim Group on Friday, June 30.

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $22.51 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company has market cap of $18.65 million. The firm is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen for post-breast cancer and preventative therapy, as well as a potential therapy for breast density and other breast health conditions. It currently has negative earnings. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as makes and sells various medical devices primarily consisting of tools to assist breast surgeons.